Vaccines

What lies beyond COVID-19? There are many diseases that could benefit from all the collaborative effort and funding being poured into COVID-19.

A look at the past, present, and future of vaccine production – and how COVID-19 changes the outlook.

Pfizer and BioNTech claim their two-dose COVID-19 mRNA vaccine (BNT162b2) is more than 90 percent effective.

We ask medicine makers around the world to tell us how their professional and personal lives have changed over the course of the COVID-19 crisis.

When following COVID-19 research, it’s hard to keep your eye on the ball...

A vaccine must be able to reach patients who need it. Reliable partners and procedures are a must.

Global access to the vaccine is essential to provide protection against the virus. A big hurdle to accessibility will likely be price.

Most clinical trials against COVID-19 exclude the very patients most at risk from the disease.

A typical vaccine takes around 10 to 12 years to reach the market. A key question: “Where should we base production?”

Nominations are now open for The Medicine Maker 2021 Power List.